Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 3

Epidemiology, Prevalence and Incidence in Wet-Form (Neovascular) Age-Related Macular Degeneration

Yaş Tip (Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Epidemiyoloji, Prevalans ve İnsidans

Pages
161–166
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To identify risk factors for AMD as a global health problem, to take necessary preventions for public health will decrease both its incidence and prevalence

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age-related macular degeneration (AMD) is one of the most common leading causes of severe, irreversible visual impairment.
📊
Key Findings & Data:Due to the increase in the mean population age mainly in developed countries, both the incidence and prevalence of AMD are progressively increasing.
💡
Conclusion & Impact:To identify risk factors for AMD as a global health problem, to take necessary preventions for public health will decrease both its incidence and prevalence
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Age-related macular degeneration (AMD) is one of the most common leading causes of severe, irreversible visual impairment. Due to the increase in the mean population age mainly in developed countries, both the incidence and prevalence of AMD are progressively increasing. It is projected that 196 million people will be affected by AMD in 2020, increasing to 288 million by 2040. It causes nearly 40 % decreases in quality of life which is similar to permanent renal dialysis or severe cardiac angina. To identify risk factors for AMD as a global health problem, to take necessary preventions for public health will decrease both its incidence and prevalence

Özet

Yaşa bağlı maküla dejenerasyonu (YBMD) geri dönüşü olmayan ciddi görme kaybına yol açan en önemli hastalıklardan biridir. Özellikle gelişmiş ülkelerde yaşam süresinin uzamasıyla insidansı ve prevalansı giderek artmakta, 2020 yılında yaklaşık olarak 196 milyon kişide YBMD gelişeceği, bu oranın 2040 yılında 288 milyona ulaşacağı öngörülmektedir. İnsidans ve prevalansının progresif olarak artmasının yanı sıra, yaşam kalitesini de ciddi oranda etkilemekte, orta düzey YBMD bile yaşam kalitesini %40 oranında azaltmaktadır. Bu oran renal diyalize bağlı olmak ya da ciddi anjina geçirmeyle aynı düzeydedir. Global bir toplum sağlığı problemi olan YBMD'de risk faktörlerinin belirlenmesi toplum sağlığı için gerekli önlemlerin alınması insidans ve prevalansın azalmasını sağlayacaktır

🔖

Cite This Article

ALTINTAŞ, A. G. K. (2017). Epidemiology, Prevalence and Incidence in Wet-Form (Neovascular) Age-Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 3, 161–166. https://ajindex.com/articles/193473

References (14)

  1. Aged –Related Macular Degeneration in Basic and Clinical Science Course Retina and Vitreous Section 12 American Academy of Ophthalmology San Francisco,CA 2014-2015 pp 1-52 2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014
  2. 2(2):e106-16. 3. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992
  3. 99(6):933-43 4. Klein R, Klein BE, Tomany SC et al. Ten year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 2002
  4. 109(10):1767-79 5. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004
  5. 72 6. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results. AREDS report no. 11. Arch Ophthalmol 2013
  6. 4 7. Chew EY, Clemons TE, Argon E, et al. Age-Related Eye Disease Study Research Group. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36 JAMA Ophthalmol 2014
  7. 7 8. Augood CA, Vingerling JR, Jong PTVM, et al. Prevalence of age-related maculopathy in older Europeans. Arch Ophthalmol 2006
  8. 124(4):529-34 9. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequel of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012
  9. 2163–96. 10. The Eye Disease Prevalence Research Group. Prevalence of age-related macular degeneration in United States. Arch Ophthalmol 2004
  10. 572 11. Van Leuven R, Laver CCW, Vingerling JR, Hoffman A, de Jong PVTM. The risk and natural course of age-related maculopathy. Arch Ophthalmol.2003
  11. 526 12. Vingerling JR, Klaver CC, Hofman A, de Jong PT. Epidemiology of age-related maculopathy. Epidemiol Rev 1995
  12. 60 13. Hawkins BS, Bird A, Klein R, Sheila KW. Epidemiology of age-related macular degeneration. Molecular Vision1999
  13. 30 14. Risk factors for the incidence of Advanced Age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) Report No 19 Ophthalmol. 2005
  14. 39 15. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular d